Cargando…

Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non‐small cell lung cancer in a single center

BACKGROUND: Adjuvant chemotherapy (ACT) can reduce the risk of recurrence and improve survival after surgical resection in non‐small cell lung cancer (NSCLC) patients. We explore the optimal time from surgery to initiation of ACT in Chinese patients with stage IIIA NSCLC. METHODS: Patients pathologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yixiang, Zhai, Xiaoyu, Chen, Sipeng, Wang, Ziping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930958/ https://www.ncbi.nlm.nih.gov/pubmed/27385981 http://dx.doi.org/10.1111/1759-7714.12342

Ejemplares similares

Impact of age on adjuvant chemotherapy after radical resection in patients with non–small cell lung cancer
por: Zhai, Xiaoyu, et al.
Publicado: (2016)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?
por: Liu, Yutao, et al.
Publicado: (2017)

Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer
por: Lei, Tao, et al.
Publicado: (2016)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2016)

Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection
por: Akazawa, Yuki, et al.
Publicado: (2017)

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study
por: Wisnivesky, Juan P, et al.
Publicado: (2011)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial
por: Park, Cheol-Kyu, et al.
Publicado: (2022)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Adjuvant chemotherapy for completely resected IIA–IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Surgical Management of Stage IIIA Non-Small Cell Lung Cancer
por: Van Schil, Paul E., et al.
Publicado: (2017)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study
por: Oki, E., et al.
Publicado: (2021)

Adjuvant Chemotherapy Following Surgical Resection Improves Survival in Patients With Early Stage Small Cell Lung Cancer
por: Yao, Yuanshan, et al.
Publicado: (2019)

Surgical resection of orbital primitive neuroectodermal tumor without adjuvant chemotherapy
por: Mehmood, Faizan, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Risk factors of brain metastases as initial failure in completely resected stage IIIA(N2) non-small cell lung cancer
por: Zhang, Qin, et al.
Publicado: (2020)

Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I–IIIA non-small cell lung cancer patients
por: Jia, Bo, et al.
Publicado: (2021)

Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I–IIIA small-cell lung cancer: a retrospective single-arm clinical trial
por: Liu, Jiacong, et al.
Publicado: (2022)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
por: Tanizaki, Junko, et al.
Publicado: (2023)

The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer
por: Wang, Jiangfeng, et al.
Publicado: (2021)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Impact of Adjuvant Chemotherapy in Patients With Curatively Resected Stage IV Colorectal Cancer
por: Kobayashi, Hirotoshi, et al.
Publicado: (2015)

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
por: Herbst, Roy S., et al.
Publicado: (2023)

The Prognostic Significance of Multiple Station N2 in Patients with Surgically Resected Stage IIIA N2 Non-small Cell Lung Cancer
por: Lee, Jin Gu, et al.
Publicado: (2008)

Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial
por: Lei, Jie, et al.
Publicado: (2023)

Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
por: Lowczak, Anna, et al.
Publicado: (2020)

Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis
por: Xu, Ya-Ping, et al.
Publicado: (2015)

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy
por: Yang, Hui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ffqk1bkd977vkqscvcg7c2444